William Blair Lowers Earnings Estimates for PTC Therapeutics

Key Points

• William Blair has lowered its FY2025 earnings per share forecast for PTC Therapeutics to $6.00 from $6.14, while the current consensus estimate indicates a loss of $4.52 per share.
• During its last quarterly report, PTC Therapeutics posted an EPS of $10.04, significantly exceeding analysts' expectations and revealing a net margin of 33.56% despite a 9.6% decline in revenue year-over-year.
• A range of analysts have adjusted their price targets for PTC Therapeutics, with some raising their price objectives, indicating a generally positive outlook despite the recent earnings forecast downgrade.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Investment analysts at William Blair cut their FY2025 earnings per share (EPS) estimates for shares of PTC Therapeutics in a report issued on Tuesday, July 29th. William Blair analyst S. Corwin now expects that the biopharmaceutical company will post earnings of $6.00 per share for the year, down from their prior estimate of $6.14. The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share.

A number of other research analysts also recently weighed in on the company. Truist Financial lifted their price target on PTC Therapeutics from $80.00 to $86.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. JPMorgan Chase & Co. lowered their price target on PTC Therapeutics from $75.00 to $67.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Citigroup lifted their price target on PTC Therapeutics from $40.00 to $50.00 and gave the company a "neutral" rating in a report on Monday, July 28th. Barclays lifted their price target on PTC Therapeutics from $42.00 to $46.00 and gave the company an "equal weight" rating in a report on Tuesday, July 29th. Finally, Robert W. Baird lowered their price target on PTC Therapeutics from $70.00 to $66.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, PTC Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $69.38.

PTC Therapeutics Trading Up 0.0%

Shares of PTC Therapeutics stock traded up $0.02 on Wednesday, reaching $52.13. 1,020,621 shares of the company were exchanged, compared to its average volume of 1,123,253. The stock has a fifty day moving average price of $49.21 and a 200-day moving average price of $48.75. The firm has a market capitalization of $4.13 billion, a price-to-earnings ratio of 8.01 and a beta of 0.54. PTC Therapeutics has a fifty-two week low of $29.01 and a fifty-two week high of $58.38.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 earnings per share for the quarter, beating the consensus estimate of $0.85 by $9.19. PTC Therapeutics had a negative return on equity of 78.56% and a net margin of 33.56%. The firm had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $437.16 million. During the same quarter in the previous year, the business earned ($1.20) EPS. The firm's revenue for the quarter was down 9.6% on a year-over-year basis.

Insider Activity at PTC Therapeutics

In other PTC Therapeutics news, CFO Pierre Gravier sold 2,516 shares of the company's stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $49.46, for a total value of $124,441.36. Following the completion of the transaction, the chief financial officer owned 71,920 shares of the company's stock, valued at $3,557,163.20. This represents a 3.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Mark Elliott Boulding sold 1,929 shares of the company's stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $46.18, for a total value of $89,081.22. Following the completion of the sale, the vice president owned 103,901 shares in the company, valued at approximately $4,798,148.18. This represents a 1.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,328 shares of company stock valued at $254,158. Insiders own 5.50% of the company's stock.

Institutional Investors Weigh In On PTC Therapeutics

Large investors have recently bought and sold shares of the business. American Century Companies Inc. lifted its stake in shares of PTC Therapeutics by 66.8% in the 4th quarter. American Century Companies Inc. now owns 60,150 shares of the biopharmaceutical company's stock valued at $2,715,000 after purchasing an additional 24,090 shares during the period. Sei Investments Co. bought a new position in PTC Therapeutics during the 4th quarter worth about $238,000. KLP Kapitalforvaltning AS bought a new position in PTC Therapeutics during the 4th quarter worth about $646,000. Vanguard Group Inc. increased its holdings in PTC Therapeutics by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 9,178,822 shares of the biopharmaceutical company's stock worth $414,332,000 after purchasing an additional 53,688 shares in the last quarter. Finally, Alliancebernstein L.P. increased its holdings in PTC Therapeutics by 62.9% during the 4th quarter. Alliancebernstein L.P. now owns 361,644 shares of the biopharmaceutical company's stock worth $16,325,000 after purchasing an additional 139,596 shares in the last quarter.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.